Other Vaccines - Denmark

  • Denmark
  • Denmark's Other Vaccines market is estimated to achieve a revenue of US$128.70m in the year 2024.
  • Projections indicate that this revenue will experience an annual growth rate (CAGR 2024-2028) of 9.12%, ultimately leading to a market volume of US$182.50m by 2028.
  • When compared globally, it is noteworthy that United States is expected to generate the highest revenue in this market, with a staggering amount of US$23,850.00m in 2024.
  • Denmark's focus on public health and strong vaccination infrastructure has led to a high demand for other vaccines in the market.

Key regions: United Kingdom, China, Europe, India, France

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

The Other Vaccines market in Denmark has shown a steady growth in recent years.

Customer preferences:
Denmark has a strong national vaccination program that covers a wide range of diseases. However, there is still a demand for other vaccines that are not covered by the national program. Customers in Denmark are highly educated and well-informed, which has led to an increase in demand for vaccines that can protect against specific diseases. Additionally, there is a growing trend towards preventive healthcare in Denmark, which has also contributed to the growth of the Other Vaccines market.

Trends in the market:
The Other Vaccines market in Denmark has seen a significant increase in demand for vaccines that protect against travel-related diseases. This is due to the fact that Denmark has a high percentage of citizens who travel abroad for business or pleasure. As a result, vaccines such as yellow fever, typhoid, and hepatitis A have become increasingly popular. Another trend in the market is the growing demand for vaccines that protect against sexually transmitted diseases, such as HPV. This is in line with the global trend of increasing awareness of the importance of sexual health.

Local special circumstances:
Denmark has a highly developed healthcare system that provides universal access to healthcare for all citizens. This has led to a high level of trust in the healthcare system and healthcare professionals. Additionally, Denmark has a relatively small population, which has made it easier to implement a national vaccination program. However, there has been some controversy in recent years regarding the safety and efficacy of vaccines, which has led to a small but vocal anti-vaccination movement.

Underlying macroeconomic factors:
Denmark has a strong economy with a high standard of living, which has led to an increase in healthcare spending. Additionally, the Danish government has made a concerted effort to promote preventive healthcare, which has led to an increase in demand for vaccines. The high level of education and awareness among Danish citizens has also contributed to the growth of the Other Vaccines market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Key Players
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Kisara Mizuno
Kisara Mizuno
Senior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)